Global Histology and Cytology Market Research Report 2021: Increase in Awareness Programs for Cervical Cancer Screening - Forecast to 2028 - ResearchAndMarkets.com
The global histology and cytology market size is expected to reach USD 37.10 billion by 2028 and is expected to expand at a CAGR of 14.74% from 2021 to 2028.
The factors contributing to the market growth include an increase in the demand for the early detection of diseases, increased standardization of pathology laboratories, and implementation of immunohistochemistry and innovation in microscopy.
In addition, organizations are collaborating for the standardization of cytopathology across the world, which is driving the market. For instance, in May 2020, the International Agency for Research on Cancer (IARC) entered in collaboration with the International Academy of Cytology (IAC) for publishing a series of cytopathology reporting systems for presenting an international approach that can be used for cytopathology of different body sites. The two organizations are engaged in the expansion and development of internationally recognized diagnostic reports for cancer and other precancerous disorders worldwide.
Moreover, companies are launching new and automated instruments for cytology, which is further contributing to the market growth. For instance, in January 2021, F. Hoffmann-La Roche Ltd. launched uPath HER2 Dual ISH image analysis and uPath HER2 (4B5) image analysis - two automated digital pathology algorithms for breast cancer. These two solutions offer rapid and accurate patient diagnoses in breast cancer.
COVID-19 has become a catalyst for changing traditional pathology workflows with the integration of artificial intelligence (AI) and digitalization solutions. During the pandemic, these tools have helped and continue to assist in remote reviewing of pathological cases, hence preventing the delay in patient care. Companies have reported the increasing adoption of digital pathology solutionspost-COVID-19.
Histology And Cytology Market Report Highlights
Based on type of examination, cytology accounted for the largest revenue share in 2020 and is expected to maintain its lead in the forecast period owing to the integration of computational analytical tools for advancing cytology systems. Histology is expected to witness gradual growth from2021 to 2028 owing to moderate innovation in histological systems
In the cytology segment, by application, the other cancers segment held the largest share in 2020 owing to the increasing diagnosis of various cancers such as pancreatic cancer and bile duct cancer with histopathology and cytopathology. The cervical cancer segment is expected to witness the fastest growth over the forecast period. Institutes are integrating computer algorithms for improving the accuracy and efficiency of cervical cancer screening
The breast cancer segment held the second-largest share in 2020 owing to the increasing incidence and mortality rates across the globe. This has resulted in the increasing need for the early diagnosis of breast cancer, in turn, driving the segment
By product, the consumable and reagents segment dominated the market in 2020 owing to the expanding portfolios of the entities operating in the consumable market space. Instruments and analysis software system is expected to expand at a substantial CAGR from 2021 to 2028 owing to the steep increase in the demand for automated histology instruments
In terms of application, the drug discovery and designing segment accounted for the largest revenue share in 2020 owing to the growing importance of cytopathology in disease understanding, further aimed at rapid drug development
North America dominated the market in 2020 owing to the prevalence of cancer, the presence of key players, and developed healthcare infrastructure
Market Dynamics
Market Driver Analysis
Rising incidence of cancer
Technological developments
Increase in awareness programs for cervical cancer screening
Market Restraint Analysis
Low sensitivity of cytology tests
Conditions required for specimens and problem of mislabeled specimens
Penetration and Growth Prospect Mapping for Products, 2020 (USD Million)
Business Environment Analysis
SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
Porter's Five Forces Analysis
Regulatory Framework
U.K.
U.S.
CLIA Law-October 31, 1988
CLIA Law-October February 28, 1992
Reimbursement Scenario
Research Institutes: Histology and Cytology Market
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent...
Predictmedix Inc. ("Predictmedix" or the "Company") (FRA:3QP), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), is pleased to announce significant progress in...
Draganfly Inc. ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., a pioneer in drone safety systems aimed at...
LiveWire Group, Inc. ("LiveWire" or the "Company") today reported first quarter 2024 results.
"We are pleased with the successful launch of the S2 Mulholland, and with three bikes in market, we are proud that LiveWire is now the #1 on-road...
Newmont Corporation (Newmont or the Company) today announced first quarter 2024 results and declared a first quarter dividend of $0.25 per share.
"Newmont delivered a strong first quarter operational performance, producing 2.2 million gold...